<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01260987</url>
  </required_header>
  <id_info>
    <org_study_id>H-1-2010-044</org_study_id>
    <secondary_id>2010-020179-22</secondary_id>
    <nct_id>NCT01260987</nct_id>
  </id_info>
  <brief_title>Fractional CO2 Laser Assisted Photodynamic Therapy</brief_title>
  <official_title>Conventional Versus Fractional CO2 Laser Assisted Photodynamic Therapy for Basal Call Carcinomas and Actinic Keratoses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nodular Basal Cell Carcinomas:

      Compare the efficacy and safety of conventional versus fractional laser assisted PDT for
      difficult to treat nodular cell carcinomas in the face.

      Actinic keratosis:

      Compare the efficacy and safety of conventional versus fractional laser assisted PDT for
      moderate to severe actinic keratoses located in the face and on the hands.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment response</measure>
    <time_frame>3 months</time_frame>
    <description>Clinical evaluation by a blinded physician.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reoccurrence</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical evaluation by a blinded physician</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment response</measure>
    <time_frame>12 months</time_frame>
    <description>Blinded histological examination from patients with basal cell carcinomas</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>during laser and PDT</time_frame>
    <description>Patient score (VAS 0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>12 months</time_frame>
    <description>scaring, hyper- and hypopigmentation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluorescence</measure>
    <time_frame>3 hours</time_frame>
    <description>Methyl-amonolevulinate uptake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic result</measure>
    <time_frame>12 months</time_frame>
    <description>4-point scale</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Actinic Keratosis</condition>
  <condition>Basal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>AK split-face treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Split-face treatment of two symmetrical areas with moderate to severe actinic keratoses. One area is treated with conventional PDT the other with fractional laser assisted PDT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fractional laser assisted PDT for BCC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Difficult to treat nodular basal cell carcinomas in the face is pretreated with fractional CO2 laser followed by methyl-aminolevulinate PDT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Konventional PDT for BCC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Difficult to treat nodular basal cell carcinomas in the face is treated with methyl-aminolevulinate PDT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional photodynamic therapy</intervention_name>
    <description>Photodynamic therapy using methyl-aminolevulinate and red light (37 J/cm2)</description>
    <arm_group_label>AK split-face treatment</arm_group_label>
    <arm_group_label>Konventional PDT for BCC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fractional CO2 laser assisted PDT</intervention_name>
    <description>Pretreatment with fractional CO2 laser before methyl-aminolevulinate PDT</description>
    <arm_group_label>AK split-face treatment</arm_group_label>
    <arm_group_label>Fractional laser assisted PDT for BCC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older

          -  Skin type I-III

          -  Fertile women using secure birth control

          -  Moderate to severe actinic keratoses in the face or on the hands,

          -  Difficult to treat nodular basal cell carcinomas in the face

        Exclusion Criteria:

          -  Pregnancy or breast feeding patients

          -  Patients with porphyria

          -  Patients with Gorlins syndrome

          -  Patients with a tendency to produce hypertrophic scars or keloids

          -  Patients with known allergy to Metvix

          -  Patients who are not considered able to follow the treatment protocol (e.g. severely
             alcoholic, dementia, mentally ill etc.)

          -  Patients with pigmented or morphea basal cell carcinomas

          -  Know herpes simplex virus infection in treatment areas
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merete HÃ¦dersdal, PhD,DrMedSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Dermatology, Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2010</study_first_submitted>
  <study_first_submitted_qc>December 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2010</study_first_posted>
  <last_update_submitted>July 29, 2015</last_update_submitted>
  <last_update_submitted_qc>July 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Christina Haak</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Moderate to severe actinic keratoses</keyword>
  <keyword>Difficult to treat nodular basal cell carcinomas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
    <mesh_term>Methyl 5-aminolevulinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

